Femasys stock.

146.71. +1.95%. 45.70M. View today's Femasys Inc stock price and latest FEMY news and analysis. Create real-time notifications to follow any changes in the live stock price.HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has activated enrollment for its FemBloc trial to investigate a permanent birth control candidate. Shares of FEMY are moving higher on very heavy trading volume.Shares of biomedical firm Femasys soared on Thursday.; Management announced the issuance of a notice of allowance for its patent application. FEMY stock soared on IP protection of its first-of-its ...Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...

Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00.

John Dyett has not been actively trading shares of Femasys over the course of the past ninety days. Most recently, on Wednesday, June 23rd, John Dyett bought 53,500 shares of Femasys stock. The stock was acquired at an average cost of $12.93 per share, with a total value of $691,755.00. Learn More on John Dyett's trading history.Nov 28, 2023 · Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an intraday high of $4.75 a few days ...

Femasys has received 510 (k) Clearance from the FDA for FemaSeed®, an innovative infertility treatment. The clearance allows for the U.S. commercialization of FemaSeed®, which delivers sperm directly to the fallopian tube. FemaSeed® is expected to reduce procedural complications compared to other treatments.Historical Stock Quote. Investment Calculator. Amount ($) Start Date: End Date: Compare to: S&P 500. Nasdaq 100. Dow 30. Other. Reinvest Dividends. Calculate Investment. ... At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party.Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.Femasys Inc. (FEMY) Stock Price, Quote, News & Analysis Breaking - Micron boosts Q1 guidance due to improved supply and demand, pricing FEMY Femasys Inc. Stock Price & Overview 657...Femasys (NASDAQ:FEMY) filed a prospectus related to the offer and resale by the selling stockholders of up to an aggregate of 18.11M shares of common stock This prospectus is not an offer to sell.

Wall Street’s analysts know that buying low is part of a winning stock strategy, and they’ve been looking for stocks that are low – undervalued, and possibly hitting bottom. It’s the first step in an old formula for success, with the next, of course, being to sell high. Some recent picks from the analyst corps, pulled up via the TipRanks platform, may raise …

Electronic Technology. Industry. Electronic Equipment/Instruments. No executives to display. Corporate headquarters. --, --. Find real-time FEMY - Femasys Inc stock quotes, company profile, news ...

Contact Us U.S. markets close in 1 hour 33 minutes (+0.48%) +243.30 +55.71 Russell 2000 +45.56(+2.52%) Crude Oil -1.60(-2.11%) Gold (+1.60%) Femasys Inc. (FEMY) NasdaqCM - NasdaqCM Real Time... LifeSci Advisors, LLC. 917-741-7792. [email protected]. Femasys Inc. Investor Contact: [email protected]. Media Contact: [email protected]. - The 510 (k) Clearance from the United States Food ...- FemaSeed ® is the first-ever, first-line approach designed to deliver sperm directly where conception occurs -. ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in …An Atlanta woman-founded, women's healthcare company plans to raise $40 million in an initial public stock offering. Suwanee-based Femasys Inc. says in plans filed May 14 with the Securities and ...What is the target price for Femasys (FEMY) stock? The latest price target for Femasys ( NASDAQ: FEMY) was reported by HC Wainwright & Co. on Tuesday, November 14, 2023. The analyst firm set a ...

Jul 27, 2023 · Shares of biomedical firm Femasys soared on Thursday.; Management announced the issuance of a notice of allowance for its patent application. FEMY stock soared on IP protection of its first-of-its ... On June 22, 2021, Femasys Inc. (the “Company”) filed an eleventh amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the completion of the Company’s initial public offering of its common stock (the “IPO”).According to 3 stock analysts, the average 12-month stock price forecast for Femasys stock is $9.00, which predicts an increase of 845.18%. The lowest target is $7.00 and the highest is $10. On average, analysts rate Femasys stock as a strong buy.Nov 30, 2023 · Why Is Femasys (FEMY) Stock Up 181% Today? investorplace.com - September 26 at 9:11 AM. Femasys up 205% as FDA clears fertility treatment. seekingalpha.com - September 25 at 11:56 PM. Femasys Secures FDA 510 (k) Clearance To Market FemaSeed. markets.businessinsider.com - September 25 at 6:56 PM. Under the terms of the investment, the investors were also issued two series of warrants: warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.18 per ...Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...

Get Femasys Inc (FEMY.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

Dec 2, 2023 · Femasys Inc (NASDAQ:FEMY) trade information. Femasys Inc (FEMY) registered a -2.33% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.33% in intraday trading to $0.93 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -9.71%, and it has moved by -33.09% in ... Nov 28, 2023 · Femasys, a medical device company, is set to launch its minimally invasive reproductive health products for women in 2024. ... Its stock ran from $0.33 to an intraday high of $4.75 a few days ... ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …Latest Femasys News: View FEMY news and discuss market sentiment with the investor community on Public.com.Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …

Jun 18, 2021 · In addition, Femasys has granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts ...

Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00.

Under the terms of the investment, the investors were also issued two series of warrants: warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.18 per share expiring one year from issuance and warrants to purchase approximately 5.8 million shares of common stock at an exercise price of $1.475 per …Comparatively, 16.4% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Earnings & Valuation. This table compares Beyond Air and Femasys’ revenue, earnings per share …52 Wk Low 0.25 52 Wk High 4.75 Avg. Volume 1,640,879 Market Cap 22.30 M Dividend 0.00 ( 0.00%) Beta NA Key Earnings Data Earnings ESP 0.00%WebFemasys Inc (NASDAQ:FEMY) trade information. Femasys Inc (FEMY) registered a -2.33% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.33% in intraday trading to $0.93 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -9.71%, and it has moved …Sep 27, 2023 · Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including FemaSeed ® an FDA- cleared infertility treatment, FemBloc ® a lead late-clinical stage product candidate for permanent birth control, and FDA-cleared, innovative diagnostic products. PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (PharmaCyte or the Company) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (Femasys), a biomedical company focused on meeting... Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update Globe Newswire • …Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in ...Zacks Rank: FEMY currently carries a Zacks Rank #3. Femasys Inc. Price and Consensus. Femasys Inc. price-consensus-chart | Femasys Inc. Quote. Stocks to Consider. Here are some stocks in the same ...Femasys has received 510 (k) Clearance from the FDA for FemaSeed®, an innovative infertility treatment. The clearance allows for the U.S. commercialization of FemaSeed®, which delivers sperm directly to the fallopian tube. FemaSeed® is expected to reduce procedural complications compared to other treatments.Sep 25, 2023 · Femasys has received 510 (k) Clearance from the FDA for FemaSeed®, an innovative infertility treatment. The clearance allows for the U.S. commercialization of FemaSeed®, which delivers sperm directly to the fallopian tube. FemaSeed® is expected to reduce procedural complications compared to other treatments. That’s a massive surge in trading volume compared to Femasys’ daily average of about 3.3 million shares. FEMY stock is up 180.9% as of Tuesday morning after closing out Monday down 63.2% year ...Femasys Inc ( FEMY) has fallen Tuesday morning, with the stock losing -1.54% in pre-market trading to 1.28. FEMY's short-term technical score of 47 indicates that the stock has traded less bullishly over the last month than 53% of stocks on the market. In the Medical Instruments & Supplies industry, which ranks 80 out of 146 industries, Femasys ...

Get the latest Femasys Inc. (FEMY) stock news and headlines to help you in your trading and investing decisions.WebApr 19, 2023 · In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions. At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.Instagram:https://instagram. most reliable forex brokerlpl and prudentialblackrock hedge fundindependent ria Sep 29, 2023 · Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 14. CI. Earnings Flash (FEMY) FEMASYS Reports Q3 Revenue $86,186. Nov. 14. MT. Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc. Nov. 13. Our Mission. Femasys is a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally invasive, in-office technologies for reproductive health. old quebecltd stock About Femasys Inc · Most Popular · Stocks Rankings for FEMY · Femasys Inc Vitals · Femasys Inc Competitors - Telecommunications Equipment · Top Movers Daily change%. best gme Sep 25, 2023 · Femasys’ FemBloc ® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for ... 146.71. +1.95%. 45.70M. View today's Femasys Inc stock price and latest FEMY news and analysis. Create real-time notifications to follow any changes in the live stock price.